project-idea

MetastaMap: Open Protocol + Data Repository for Ex Vivo Organ Invasion Studies

Breast cancer cells preferentially invaded lung and liver ECM scaffolds but not intestinal scaffolds in the new ex vivo assay — perfectly matching clinical metastatic tropism patterns.

The ex vivo invasion platform described in this paper fills a critical gap between oversimplified lab models and animal experiments, but its value multiplies if labs share their data. MetastaMap would be an open protocol registry and data repository where labs using ECM scaffold invasion assays can submit their results: which cancer cell lines, which organ ECMs, what invasion rates, under what conditions.

The repository would have two components: a standardized protocol registry (documenting decellularization parameters, vibratome slice thickness, channel dimensions, imaging methods) and a quantitative invasion database organized by cancer type, organ target, and cell line. Cross-lab data would allow meta-analysis of organ-specific invasion patterns across dozens of cancer types — currently impossible because each lab runs its own version of the assay.

A companion visualization layer could show heatmaps of invasion rates across organ/cancer-type combinations, surfacing new patterns and discrepancies worth investigating. This kind of infrastructure project takes time but scales with every contributing lab.

Who Is This For?

Cancer biology researchers, core facility managers, and bioinformaticians interested in metastasis research infrastructure.

Skills & Tools Needed

Web development (database + API)
Protocol standardization and metadata schema design
Data visualization (heatmaps, comparative charts)
Scientific community outreach and lab partnerships
Basic cancer biology knowledge for schema design

Feasibility

medium — Technical build is straightforward; the challenge is adoption — convincing labs to submit data to a shared resource requires community buy-in and curation effort.

Inspired by: Ex Vivo Assay for Organ-Specific Cancer Cell Invasion

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.